Cerus Corporation Announces Symposium and Abstracts at the 38th International Congress of the International Society of Blood Transfusion
Symposium and Abstracts Highlight Data from Real-world Implementation and Utilization of INTERCEPT Platelets and Plasma as well as from Red Blood Cell and LED Illuminator Programs
The following is a list of selected presentations and abstracts of interest for
Oral Presentations
-
Thursday, June 27, 2024 –12:30 p.m. – Cerus Lunch Symposium – Pathogen Inactivation: Further evidence for implementation- The natural virome and pandemic potential: Disease X
- Comparison of clinical outcomes in cardiac surgery, using INTERCEPT platelets and conventional platelets
- Benefits and challenges of implementing pathogen inactivation methods – the importance of high quality randomized clinical studies
-
Thursday, June 27, 2024 –11:15 a.m. – Quantifying Residual Red Blood Cells in Platelet and Plasma Components: Flow Cytometry and a Visual Inspection Tool Support Implementation of Pathogen Inactivation
Poster Presentations
Held between
- Cold-Storage of Amotosalen-UVA Pathogen-Reduced Buffy-Coat Platelet Concentrates for Up to 21 Days: Biochemical and Functional Characterization, and Identification of Platelet Subpopulations
- Safety of Amotosalen/UVA Platelets and Plasma Transfused In Routine Clinical Use: Real World Evidence From 2 Large European Transfusion Medicine Centers, 2019-2022
-
Introduction of 7-Day Amotosalen/UVA Pathogen Reduced Platelets In
Honduras : Impact on Platelet Availability In a Lower Middle Income Country - Amotosalen-UVA Pathogen Reduced Plasma, Cryoprecipitate Reduced (PRPCR): An Optimized Cost-Effective Component for Therapeutic Plasma Exchange
- Development of a Next Generation Illuminator for Photochemical Inactivation of a Broad Spectrum of Pathogens in Platelet Concentrates and Plasma
- Evaluation of Plasma Treated for Pathogen Reduction With Amotosalen and a Prototype LED Illuminator
ABOUT
INTERCEPT and the INTERCEPT Blood System are trademarks of
View source version on businesswire.com: https://www.businesswire.com/news/home/20240621244141/en/
925-288-6137
Source: